


 Cite this: *RSC Adv.*, 2024, 14, 30859

Insights into the molecular interactions between urease subunit gamma from MRSA and drugs: an integrative approach by STD-NMR and molecular docking studies†

 Anum Fatima, ^a M. Iqbal Choudhary, ^{*abc} Shezaib Siddiqui, ^a Humaira Zafar, ^{*a} Kaifeng Hu ^d and Atia-tul Wahab ^{*a}

Staphylococcus aureus, an important human pathogen, is developing resistance against a wide range of antibiotics. The antibiotic resistance in *S. aureus* has created the need to identify new drug targets, and to develop new drugs candidates. In the current study, urease subunit gamma from Methicillin Resistant *Staphylococcus aureus* (MRSA 252) was studied as a potential drug target, through protein–ligand interactions. Urease is the main virulence factor of MRSA, it catalyzes the conversion of urea into ammonia that is required for the survival of bacteria during acid stress. Its subunits and accessory proteins can serve as targets for drug discovery and development. Present study describes the cloning, expression, and purification of urease subunit gamma from MRSA 252. This was followed by screening of 100 US-FDA approved drugs against this protein using STD-NMR spectroscopy and among them, 15 drugs showed significant STD effects. *In silico* studies predicted that these drugs interacted mainly via non-covalent interactions, such as hydrogen bond, aromatic hydrogen bonding, π – π stacking, π –cation interactions, salt bridges, and halogen bonding. The thermal stability of UreA in the presence of these interacting drugs was evaluated using differential scanning fluorimetry (DSF), which revealed a significant effect on the T_m of UreA. Additionally, the inhibitory effects of these drugs on urease activity were assessed using a urease inhibition assay with Jack bean urease. The results showed that these drugs possess enzyme inhibitory activity, potentially impacting the survival of *S. aureus*. These hits need further biochemical and mechanistic studies to validate their therapeutic potential against the MRSA infections.

 Received 6th March 2024
 Accepted 7th September 2024

DOI: 10.1039/d4ra01732c

rsc.li/rsc-advances

Introduction

Staphylococcus aureus, a clinically important pathogen, has acquired resistance to a wide range of antibiotics. To overcome this resistance, there is an urgent need to identify new drug targets, and thereby development of more effective drugs.^{1,2}

S. aureus has acquired antibiotic resistance through various mechanisms, such as drug target modification, efflux pumps activation, limiting the drug uptake, target overproduction, and drug inactivation.³ Therefore, identification of bacterial proteins,

essential for the survival and pathogenesis of the bacteria, may serve as the drug targets for the discovery of new antibiotics.⁴

Urease is one of the main contributing factors in the pathogenesis of *S. aureus* strains.^{5–7} As in 90% strains of MRSA, urease enzyme is essential to provide alkaline environment against acid stress, and thereby facilitates *S. aureus* to maintain homeostasis.^{7,8} *S. aureus* encodes ureABCEFGD gene cluster for urease enzyme, where, ureA, ureB, and ureC genes encodes to γ , β , and α subunits, respectively, that form the apoenzyme.⁵ While ureEFGD genes encodes urease accessory proteins that form the urease pre-activation complex. This complex is essential for the urease enzyme activity,⁹ as it provides nickel to the active site of the enzyme to perform its activity.¹⁰ Urease catalyzes the hydrolysis of urea into ammonia and carbonic acid.^{11,12} Ammonia serves as nitrogenous source for bacterial growth during acid stress,¹³ and is further protonated into ammonium hydroxide ions, and increases the pH of the environment, which can cause damage to host tissues as well.¹⁴

In the current study, urease subunit γ from MRSA 252 was investigated as a potential drug target through protein–ligand interactions. Urease subunit γ is a part of the bacterial urease

^aDr Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi-75270, Pakistan. E-mail: atia.tuwahab@iccs.edu; iqbal.choudhary@iccs.edu; hamramalik@gmail.com

^bH. E. J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi-75270, Pakistan

^cDepartment of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah-22254, Saudi Arabia

^dState Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan-611137, China

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4ra01732c>



apoenzyme.¹⁵ The apoenzyme further requires accessory proteins assembly to be functional, and to perform its catalytic activity.^{9,15} We hypothesized that drugs interaction with urease subunit γ may inhibit the recruitment of the accessory proteins, thus limiting the urease enzyme activity.

Saturation transfer difference (STD)-NMR is a powerful analytical technique to identify the protein–ligand interactions.¹⁶ Quantitative analysis of STD spectra can also map the binding epitopes of the ligands for their interactions with the protein.^{17,18} In this study, 100 US-FDA approved drugs (ligands) were analyzed against the urease subunit gamma by using STD-NMR spectroscopy. The drugs showing interaction with protein on STD-NMR experiments were further studied by molecular docking studies. The molecular docking predicts the interactions of these drugs with the protein. The combination of STD-NMR and molecular docking provides comprehensive valuable insights for the identification of the potential drug candidates against the urease subunit gamma. Moreover, these protein–ligand interactions can help to inhibit the urease enzyme activity, and negatively regulate the MRSA growth during acid stress. Furthermore, there is a need to study the potential of these interacting drugs as new leads for the treatment of MRSA infections.

Methodology

Cloning of urease subunit γ into the pET-25b vector

Genomic DNA of MRSA 252 was isolated using MagPrep® Bacterial Genomic DNA Kit (Cat # 71256), and urease subunit γ gene FASTA sequence was retrieved from the National Center for Biotechnology Information (NCBI). Using Oligo perfect designing tools, and Integrated DNA technology, urease subunit γ gene was amplified by PCR (Tables S1 and S2†) using the forward primer (5′CCGCATATGTTGCATTTTACAACGAGAGC-3′), and reverse primer (5′GCGAAGCTTTTAAACA-TAGGGTGATTACTGTGA-3′) with the restriction sites, NdeI, and HindIII, for the purpose to clone the gene into pET25-b vector. Agarose gel electrophoresis was performed by using Fermentas, GenRuler DNA ladder, and Fermentas 6× sample loading dye. Using DNA Gel Extraction Kit, DNA was extracted and its concentration was measured by NanoDrop 2000 spectrophotometer (Thermo Fisher, USA). GenElute™ Plasmid Miniprep Kit was used to isolate the commercially available blank pET25b vector. Restriction sites were produced using NEB HindIII, and NEB NdeI enzymes in the pET25b vector and the amplified PCR products (gene), with incubation of 2 h at 37 °C, followed by 20 min heat deactivation at 80 °C (Table S3†). Qiagen Mini Elute Reaction Cleanup Kit was used to purify the gene product and the digested vector. T4 DNA ligase was used to ligate the urease subunit γ gene into the pET25b vector at 24 °C for 1.5 h using Invitrogen kit protocol (Cat. No. 15224-017) (Table S4†), and stored at –20 °C prior to transform in *E. coli* DH5 α .

Transformation of urease subunit γ : pET25b clone in *E. coli* DH5 α , and *E. coli* BL21 (DE3) cells

After ligation of gene into the cloning vector, the plasmid was transformed into the *E. coli* DH5 α , and *E. coli* BL21(DE3) cells

according to the given CaCl₂ heat shock transformation guidelines. Transformed culture was then plated on ampicillin (100 $\mu\text{g mL}^{-1}$) (Biobasic Inc., Canada) supplemented L.B. agar plates, and incubated overnight at 37 °C. The positive colonies were picked and sequenced, allowed to grow in L.B. media and glycerol stocks were made. Further, colony PCR (Tables S5 and S6†) and DNA sequencing by Sanger's method (Macrogen Inc., Korea) was performed for the confirmation of positive clones.

Expression of urease subunit γ

E. coli BL21(DE3) cells transformed positive clones were grown in L.B. media for the expression of urease subunit γ . After induction with 1 mM isopropyl- β -D-thiogalactopyranoside (IPTG) at O.D.₆₀₀ ~ 0.6, it was incubated for another 18–20 h at 18 °C and 180 rpm before harvesting by centrifugation at 8000 rpm for 15 min at 4 °C, and the harvested cells was stored at –80 °C until next use.

Purification of urease subunit γ protein

Cell lysis was performed by ultra-sonication using buffer of pH 6.6 (20.0 mM Bis-Tris, 20.0 mM NaCl, and 1.0 mM PMSF). The buffer was selected based on protein's pI value *i.e.* 5.68, and the lysate was then centrifuged for 40 min at 14 600 $\times g$, 4 °C. The supernatant was loaded on the equilibrated anion exchange column (Hi-Trap Q column, GE Healthcare, U.K.), and the protein was eluted with the linear gradient using 1.0 M NaCl.

The eluted fractions were analyzed by SDS-PAGE and further concentrated till 5 mL. Then the sample was loaded onto 75 μg Hi-load 26/600 Superdex column (GE Healthcare, U.K.) and further purified using pH 6.5 buffer (20 mM sodium phosphate, 20 mM NaCl). The eluted protein fractions were concentrated, and quantified by using NanoDrop (Thermo Fisher Scientific, USA).

Compound library and screening procedure

For mixture analysis, a total of 100 compounds (US-FDA approved drugs) from the *in-house* library of the PCMD Molecular Bank were screened by grouping them into 20 mixtures (Table S7†). Mixtures were prepared by combining 5 mM of each compound dissolved in deuterated buffer (20 mM sodium phosphate, 20 mM NaCl, pH 6.5). The mixtures were screened at 1 mM while 50 μM of urease subunit γ was used. By employing STD-NMR experiments, mixtures were screened for potential binders against urease subunit γ from MRSA 252. This strategy efficiently reduced the experimental time to screen the library of compounds. Further, the compounds interacting in mixture were analyzed individually by STD-NMR experiments.

STD-NMR studies

The STD-NMR experiments were recorded on Bruker Avance NEO 600 MHz spectrometer (Switzerland), equipped with a cryogenically cooled probe and an automated SampleCase™. Topspin 4.5 NMR was used to process spectra. *stdiffesgp.3* Pulse program from Bruker library was used to perform the STD-NMR experiments by employing excitation sculpting for water

suppression.¹⁹ 512 Scans for mixtures and 2048 scan for individual interacting compounds were recorded to analyze the STD effect. All the experiments were recorded at 298 K by giving the selective saturation (on-resonance) at 45.062 Hz for 5 s with an interpulse delay of 10 s and the *off-resonance* was set at $-20,000$ Hz. For STD-NMR screening, first the experiments were recorded in the absence of protein (control), and then in the presence of protein. By subtracting the *on-resonance* spectra from the *off-resonance* spectra, difference spectrum was obtained. Amplification factor for the ligand protons, which showed the interaction with protein, was calculated by using the formula:

$$\text{STD amplification factor} = \left(\frac{I_o - I_{\text{sat}}}{I_o} \right) \times \text{ligand excess}$$

where, I_o and I_{sat} are signal intensities of protons in the *off-* and *on-resonance* STD-NMR spectrum, respectively.

Homology modeling

Since, the single-crystal X-ray structure of urease subunit gamma was not found in the protein data bank (PDB), template based homology modeling was performed using the online available software Swiss-Model.²⁰

Molecular docking studies

Molecular docking was performed using Maestro Schrödinger (2023-2) Glide module 6.9 for predicting the protein ligand interactions at the atomic level. The homology model was built using the crystal structure of urease subunit gamma (PDB ID: 4FUR). The protein preparation wizard was used to prepare and minimize the protein. OPLS4e force field assigned the missing protons and partial charges and PROPKA predicts the protein pK_a . Using the prime module, the missing loops and zero order bonds were assigned. The *LigPrep* tool was used to prepare the ligands by assigning relevant protonation states, and altering their torsions. Ligands ionization and tautomeric states were generated by using *Epik* prime tool. The results were analyzed by using the *Glide_XP* module for the best docked pose.

Binding energy estimation by MM-GBSA analysis

MM-GBSA (Molecular mechanics-generalized Born surface area) is commonly used to estimate the ligand binding affinity. In order to predict the binding affinity of the ligands, prime MM-GBSA tool in Schrödinger (2023-2) was used. This tool re rank the *Glide_XP* module docked conformations, and estimates the relative binding energy of the ligands. The more negative binding energy (kcal mol^{-1}) reflects stronger binding affinity of ligand.

MD simulation studies

MD simulation studies were performed by using the Desmond molecular dynamics within the Schrödinger package for a comprehensive investigation of stability of ligand-protein complexes. Initially, the selected complexes were assigned to an SPC (simple point charge) water box, extending 10 Å beyond the

complex's atoms. To neutralize charges, counter ions (33 Na^+ and 29 Cl^-) were added, and the salt concentration was set to 0.15 M sodium, and chloride ions to approximate physiological conditions. The MD simulation in the NPT ensemble was conducted at a temperature of 300 K and 1.63 bar pressure over 100 ns. The OPLS-3e force field was employed, and plots and figures were generated using the Desmond simulation interaction diagram tool of Maestro.²¹

Thermal shift assay (TSA)

Thermal shift assay was performed to analyze the effect of the drugs on the melting temperature of UreA. All the samples were prepared in 20 mM sodium phosphate buffer with 20 mM NaCl and pH 6.5. Each sample contained UreA (20 μM), ligand (drug) (2 mM), and Sypro@Orange dye 2 μL (1 : 1000; Invitrogen Life Technology, USA). Samples were prepared, and heated from 20 °C to 95 °C at rate of 0.3 °C min^{-1} using Bio-Rad Real-time PCR machine (Bio-Rad Laboratories, USA). During the temperature increment, HEX channel was used to measure the sypro-orange fluorescence intensity as a function of temperature. By comparing the melting temperature (T_m) at which half of the protein population is unfolded, differences in the thermal stability of protein were determined in the absence (control) and presence of drug molecule. Furthermore, the dissociation constant of nicotinamide was determined by observing the change in protein melting temperature at different concentrations. The concentrations used for the determination of K_d were 0.01 mM to 100 mM (0.01, 0.02, 0.05, 0.1, 0.2, 0.5, 0.7, 1, 2, 5, 7, 10, 20, 50, 70, and 100 mM) with 20 μM UreA.

Urease inhibition assay

Urease inhibition assay was performed to analyze the enzyme inhibitory activity of the drug molecules that has shown interactions in STD-NMR studies. Jack bean (*Canavalia ensiformis*) urease was used in this study, because urease subunit gamma (MRSA 252) was not enough to evaluate the urease inhibitory activity. As it is one of the subunit of urease enzyme, the catalytic activity requires the whole enzyme. Jack bean urease is a fully functional enzyme with 49% sequence similarity with the urease subunit gamma (Table S7†).

Jack bean urease (2.92 mg) was dissolved in 2.5 mL of sodium phosphate buffer (20 mM, pH 6.8). Urease enzyme (25 μL) was incubated with 5 μL of the drug (0.5 mM), and incubated for 15 min at 30 °C. Further, 55 μL of substrate urea (0.1 M urea in phosphate buffer) was added, and incubated for 15 min at 30 °C. After 15 min incubation, 45 μL phenol reagent (1% w/v phenol, 0.005% w/v sodium nitroprusside), and 70 μL of alkali reagent were added (0.5% w/v sodium hydroxide, and 0.1% sodium hypochlorite) in the reaction mixture. All the reactions were performed in triplicates, and the absorbance of the reaction mixtures, measured at 630 nm, was used to calculate the % inhibition of the drug molecules:

$$\% \text{ Inhibition} = \left(\frac{\text{O.D.}_{\text{Control}} - \text{O.D.}_{\text{Test compound}}}{\text{O.D.}_{\text{Control}}} \right) \times 100$$

Table 1 List of drugs interacting with urease subunit gamma in STD-NMR









Compound	Drug name	Structure
1	Nicotinamide	
2	Drotaverine HCl	
3	Clidinium bromide	
4	Sulfanilamide	
5	Nicorandil	
6	Hydroxychloroquine sulphate	
7	Glucosamine HCl	
8	Ephedrine	

Table 1 (Contd.)

Compound	Drug name	Structure
9	Penicillin G sodium	
10	Tramadol hydrochloride	
11	Nicotinic acid	
12	Salbutamol sulfate	
13	Bupropion hydrochloride	
14	Tenofovir disoproxil	
15	Rasagiline mesylate	

Results and discussion

Urease subunit γ gene of methicillin-resistant *Staphylococcus aureus* was cloned in pET25-b vector, and expressed by using recombinant DNA technology²² using the T7-based expression system of *E. coli* BL21(DE3) cells. The expressed protein was purified by anion exchange and gel filtration chromatography. A total of 100 drugs (grouped into 20 mixtures) were screened against urease subunit γ using STD-NMR experiments. Fifteen

drugs from 11 mixtures have shown interactions with urease subunit γ , and these were further validated individually by STD-NMR experiments, showing that they have the ability to interact with urease subunit γ . Further, molecular docking and MMGBSA analysis was performed to analyze the interactions between urease subunit γ and drug molecule in their physicochemical state, and to predict the binding affinity of drugs, respectively.

Cloning, expression and purification

The urease subunit γ gene was successfully cloned in pET25b vector (Fig. S1†), and transformed in the *E. coli* BL21(DE3) expression cells (Fig. S2†). The expression of the urease subunit gamma was found to be high, and on SDS-PAGE gel as it appears in the soluble lane at the estimated molecular weight of 11.2 kDa (Fig. S3†). Initially, the expressed protein was purified using anion exchange chromatography (Hi-Trap Q column) (Fig. S4†). Following, size exclusion chromatography on 75 μ g 26/600 Superdex column, the protein was eluted at 162 mL, and appeared to be trimeric in nature (Fig. S5†). The yield of the purified urease subunit gamma was 24 mg mL⁻¹ in 1 L of culture.

STD-NMR studies

Conventional drug development is a long and costly process that takes 10–12 years, and two billion dollars investment for a drug to be approved by drug regulatory authorities. Drug repurposing is a smart approach that identifies the new therapeutic uses of an old drug. This approach has many advantages over conventional drug discovery, including time, and cost efficiency. Hence, in the current study US FDA-approved drugs, available in the Drugs Bank of Dr Panjwani Center of Molecular Medicine and Drug Research (PCMD), were used to analyze their binding affinities with the purified urease subunit of MRSA.

Various biophysical techniques are used to study the protein–ligand interactions, such as Circular Dichroism (CD), Isothermal Titration Calorimetry (ITC), and Surface Plasmon Resonance (SPR) and many others. Saturation Transfer Difference-Nuclear Magnetic Resonance (STD-NMR) is a robust approach to identify the ligands with moderate to weak affinity. The technique is ligand based, and works on the principle of nuclear Overhauser effect (NOE). The protein is selectively

saturated and the magnetization is transferred *via* spin diffusion to the whole protein, and also to the bound ligand. As soon as the ligand is dissociated, the magnetization is detected in the solvent (buffer system).

The drugs were screened by using STD-NMR technique in the form of mixtures, and the ligands that showed binding with protein were further analyzed individually to map the ligand proximity to the protein *i.e.* group epitope mapping (GEM). Protons of the ligand which receive the highest degree of saturation indicate their close proximity to the protein. For GEM analysis, the proton receiving the highest STD integral value was set to be 100%, while the other protons' STD integrals were normalized against the most intense signal.²³ From 20 mixtures, drugs from mixtures 1–2, 6–9, 11–13, 15, and 20 showed their interactions with protein, identified as the potential binders, and further evaluated individually. Finally, 15 drugs (Table 1) showed interactions with the receptor protein (urease subunit γ).

Compound 1 (nicotinamide), an active soluble form of vitamin B3, possesses antioxidant and neuroprotective properties, and is used for the treatment of vitamin B3 deficiency (pellagra), acne, non-melanoma skin cancer, skin aging, skin discoloration, and other pathological conditions.²⁴ In this compound, H-2 of the aromatic ring received the maximum 100% saturation from the protein, while H-6 and H-5 received the 66 and 45% relative saturation, respectively (Fig. 1). The GEM analysis revealed that the H-2 lies in the closer proximity of protein.

Compound 2 (drotaverine hydrochloride) is an anti-spasmodic drug used to relieve smooth muscles' spasmodic pain.²⁵ Its GEM analysis indicated that CH₂-18 received the highest saturation from the protein. While the rest of the protons were assigned relative saturation. CH₂-20, CH₂-22 and CH₂-24 received 71.6% saturation from the protein. Further, the aromatic H-8, H-5, CH₂-13/CH₂-16 and CH₂-17 received 79.8,




Fig. 1 STD-NMR spectra of drug nicotinamide (1): (A) reference spectrum of the drug. (B) STD difference spectrum of nicotinamide in presence of urease subunit gamma, indicating the interacting protons of drug (protons interacting with protein are marked with '*'). (C) Graphical representation of percent saturation of drug proton receiving from protein.




Fig. 2 STD-NMR spectra of drug drotaverine HCl (2): (A) reference spectrum of the drug. (B) STD difference spectrum of drotaverine HCl in the presence of urease subunit gamma, indicating the interacting protons of drug (protons interacting with protein are marked with '*'). (C) Graphical representation of percent saturation of drug protons receiving from protein.

83.3, 56.3 and 40.2% saturation from the protein, respectively (Fig. 2). CH₂-3 and CH₂-4 received 21.3 and 15.4% relative saturation, respectively, from the protein. The methyl's, CH₃-19, CH₃-21/CH₃-23 and CH₃-25 received 44.3, 43, and 31% saturation, respectively. This GEM analysis revealed that CH₂-18 is closer to the protein proximity attaining the highest saturation from the protein.

Compound 3 (clidinium bromide), an anticholinergic drug, used as an antispasmodic agent to relieve abdominal cramps by inhibiting acetylcholine muscarinic action.²⁶ GEM analysis indicated that the protons of the aromatic rings (H-4/H-5/H-6/

H-7/H-8 and H-10/H-11/H-12/H-13/H-14) received the maximum saturation, and were in closer proximity to the protein (Fig. 3).

Compound 4 (sulfanilamide), a precursor of sulfonamide drugs, is a synthetic antimicrobial agent used for inhibiting folic acid synthesis in bacteria to prevent their growth and multiplication.²⁷ As compound 4 is a small molecule with single heterocyclic ring, all the aromatic protons showed interactions with protein in STD difference spectrum. The GEM analysis indicated that H-3 and H-5 received 100% saturation indicating




Fig. 3 STD NMR spectra of drug clidinium bromide (3): (A) reference spectrum of the drug. (B) STD difference spectrum of clidinium bromide in presence of urease subunit gamma, indicating the interacting protons of drug (protons interacting with protein are marked with '*').




Fig. 4 STD NMR spectra of drug sulfanilamide (4): (A) reference spectrum of the drug. (B) STD difference spectrum of sulfanilamide in presence of urease subunit gamma, indicating the interacting protons of drug (protons interacting with protein are marked with '*'). (C) Graphical representation of percent saturation of drug protons receiving from protein.

their closer proximity with the protein (Fig. 4). While H-2 and H-6 received 92% relative saturation from protein.

Compound 5 (nicorandil) is a vasodilator drug used for the treatment of angina. It works by relaxing the vascular smooth muscles to control high blood pressures.²⁸ In this compound, the GEM analysis indicated that the aromatic ring H-2 received 100% saturation from the protein (Fig. S7†). In comparison, H-6 and H-5 received 63.5 and 31.3% saturation, respectively. The results indicated that the H-2 is in closer proximity of the protein.

Compound 6 (hydroxychloroquine sulphate) is an antirheumatic drug used for the treatment of malaria, autoimmune, and viral diseases.²⁹ It also possesses antibacterial activity, and act by alkalizing the bacterial intracellular organelles thereby decreasing the bacterial survival and multiplication rate.³⁰ Through GEM analysis, it was found that the H-8 of the aromatic ring received 100% saturation from the protein (Fig. S8†). Whereas, H-6, H-2, and H-5 received 49, 42 and 34.3% relative saturation from the protein, respectively. Thus the analysis indicated the close proximity of H-8 with the protein.

Compound 7 (glucosamine HCl) is an anti-inflammatory drug used for the treatment of rheumatoid arthritis and osteoporosis.³¹ This antirheumatic drug has also been reported for antibacterial activity against the *S. aureus*.³² The GEM analysis revealed that the H-2 received 100% saturation from the protein (Fig. S9†). Whereas, the H-7 and H-7' received 67 and 54% relative saturation from protein, respectively. The STD spectrum indicated that the H-2 is in the closest proximity of the protein.

Compound 8 (ephedrine) is an adrenergic agonist drug, used for the treatment of hypotension, asthma, and nasal decongestants.³³ It also has a significant antimicrobial effect on *S. aureus* growth.³⁴ The GEM analysis of this compound revealed that H-3, H-4, and H-5 received highest saturation, and were in closer proximity of the protein (Fig. S10†). The aliphatic H-9 received 37%, and the aromatic ring H-2 and H-6 received about 30% relative saturation from the protein.

Compound 9 (penicillin G sodium) is an antimicrobial agent used to inhibit the bacterial cell walls synthesis, leading to the destruction of susceptible bacteria during infections.³⁵ According to the GEM analysis, H-6 was in closer proximity to the protein, receiving the highest saturation, while the H-5 received 59% relative saturation (Fig. S11†).

Compound 10 (tramadol hydrochloride) is a synthetic opioid analgesic used to relieve severe to moderate pain, it binds with the opioid receptors in the central nervous system.³⁶ This opioid analgesic is also reported for its *in vitro* activity against the *S. aureus*.³⁷ The GEM analysis of the compound 10 indicated that H-8 and H-12 of aromatic ring received the highest saturation from the protein, while H-10 has received 35.9% relative saturation from protein. This indicated that H-8 and H-12 were closer to the protein (Fig. S12†).

Compound 11 (nicotinic acid) is a form of vitamin B3, used for the treatment of pellagra. It has the ability to maintain the human cholesterol level.³⁸ It can also facilitate the neutrophils to perform their functions more efficiently at the site of infection.³⁹ The drug showed weak STD interaction, as only H-5 of

the aromatic ring showed STD effects, while rest of the protons did not show any STD signals (Fig. S13†).

Compound **12** (salbutamol sulfate) is a β 2-adrenergic receptor agonist used as bronchodilator for the treatment of asthma and COPD. It relaxes the smooth muscles of the lungs airways.⁴⁰ In 2015, Vandeveldel *et al.* reported for the first time that the salbutamol may contribute in the biofilm eradication of the *S. pneumoniae*.⁴¹ For compound **12**, the GEM analysis indicated that aromatic H-3 received the highest saturation, indicating its closer proximity to the protein (Fig. S14†). While, H-5 received 74.9% relative saturation.

Compound **13** (bupropion hydrochloride) acts as an antidepressant by increasing the level of dopamine and serotonin in the brain, and also helps smokers to overcome their nicotine addiction.⁴² According to GEM analysis, H-2 of the aromatic ring is in closer vicinity of the protein by receiving the highest saturation, and H-4 and H-5 received 43.3 and 30.3% relative saturation, respectively (Fig. S15†).

Compound **14** (tenofovir disoproxil) is a nucleoside reverse transcriptase inhibitor, used for the treatment of HIV, and hepatitis B infections.⁴³ The GEM analysis revealed that the methylene protons, such as CH₂-14 and CH₂-19 and H-16/H-21 were in closer proximity as they received the maximum saturation, while the H-8 received 11.8% and CH₃-17, CH₃-18, CH₃-22 and CH₃-23 received 9.8% relative saturation from protein (Fig. S16†).

Compound **15** (rasagiline mesylate), a monoamine oxidase B, selective irreversible inhibitor, is used for the treatment of Parkinson's disease by maintaining the dopamine levels in the CNS.⁴⁴ In this compound, maximum saturation was received by the H-12 *i.e.* 100% and was used to normalize the other protons (Fig. S17†). In comparison, the aromatic ring H-1, and H-3 received 56.6 and 29.3%, respectively. Whereas, the H-2 and H-4 of aromatic ring received 27.2% relative saturation. The GEM analysis showed that the H-12 was in the close proximity of the protein.

According to GEM analysis of the interacting drugs, it is predicted that mostly the protons of the aromatic ring have high affinity and interact with the urease subunit gamma. While the protons at the aliphatic region showed a weak interaction with the protein.

Molecular docking studies

Molecular docking studies were performed for the prediction of protein–ligand interactions at atomic level. Since 3D structure of urease gamma subunit has not been elucidated till date, the homology model was built using crystal structure of urease subunit gamma 2 from *Brucella melitensis* biovar Abortus 2308 (PDB ID: 4FUR), that showed 52% similarity with the urease subunit gamma of MRSA252.

Molecular docking studies provided further insights about the interactions of drug molecules with various amino acids of

Table 2 Protein–drug interactions between drugs and urease subunit γ amino acids

Drug	Name	Amino acid	Molecular interactions with protein	Docking score	Binding energy, kcal mol ⁻¹
1	Nicotinamide	Thr85	Hydrogen bond	-5.979	-28.81
2	Drotaverine HCl	Thr85	Aromatic H-bond	-3.673	-67.40
3	Clidinium bromide	Lys10, Arg23 Asn31	π -cationic interactions Hydrogen bond	-5.086	-62.07
4	Sulfanilamide	Glu7, Ala16	Aromatic H-bond	-6.311	-26.89
5	Nicorandil	Lys10, Arg23, Thr85 Lys10	Hydrogen bond Salt bridge	-4.320	-33.02
6	Hydroxy-chloroquine sulphate	Glu34, Thr85 Leu44, Thr85 Glu34	Hydrogen bond Aromatic H-bond Salt bridge	-5.907	-50.69
7	Glucosamine hydrochloride	Glu7, Arg23, Asn31, Glu34	Hydrogen bond	-4.713	-26.69
8	Ephedrine	Glu7 Phe3 Arg23 Ala16	Hydrogen bond π - π stacking interactions π -cationic interactions Aromatic H-bond	-6.204	-40.53
9	Penicillin G sodium	Lys10, Asn31, Thr85 Lys10 Phe3	Hydrogen bond Salt bridge π - π stacking interactions	-6.565	-49.57
10	Tramadol HCl	Arg23	π -cationic interactions	-5.930	-62.14
11	Nicotinic acid	Lys10 Lys10 Leu44	Hydrogen bond Salt bridge Aromatic H-bond	-5.368	-22.05
12	Salbutamol sulfate	Glu34, Thr85 Glu34	Hydrogen bond Salt bridge	-6.236	-58.77
13	Bupropion HCl	Thr85	Halogen bond	-5.113	-53.79
14	Tenofovir disoproxil		No interaction	-4.299	-64.59
15	Rasagiline mesylate	Phe3 Ala16 Arg23	π - π stacking interactions Aromatic H-bond π -cationic interactions	-4.969	-43.53

the urease subunit gamma. The docking scores were in the range of -6.024 to -3.673 . All the drugs interacted *via* various non-covalent interactions with enzyme, such as hydrogen, aromatic hydrogen bonds, π - π stacking, π -cationic interactions, and salt bridge formation (Table 2).

Compounds **1** (nicotinamide), and **2** (drotaverine hydrochloride) interacted with Thr85 *via* hydrogen and aromatic hydrogen bonds, respectively (Fig. S18, and S19[†]). Compound **3** (clidinium bromide) interacted with Asn31 and Glu7 *via* hydrogen, and aromatic hydrogen bonding (Fig. 5). The phenyl rings of the compound **3** interacted with the Lys10 and Arg23 *via* π -cation interactions.

Compound **4** (sulfanilamide) interacted *via* hydrogen bonds with the Glu7 and Ala16 residues of urease subunit gamma (Fig. S20[†]). Compound **5** (nicorandil) interacted with Lys10, Arg23, and Thr85 by hydrogen bonding, and salt bridge were formed with the Lys10 (Fig. S21[†]). Compound **6** (hydroxychloroquine sulphate) form hydrogen and aromatic hydrogen bonds with Glu34 and Thr85, Leu44 and Thr85, respectively (Fig. S22[†]). It also interacted with Glu34 by forming a salt bridge. Compound **7** (glucosamine HCl) showed interactions with Glu7, Arg23, Asn31, and Glu34 by hydrogen bonding (Fig. S23[†]). Compound **8** (ephedrine) interacted *via* hydrogen and aromatic hydrogen bond with Glu7, Ala16, respectively (Fig. 6). The phenyl ring interacted with Phe3, and Arg23 *via* π - π stacking, and π -cationic interactions, respectively.

Compound **9** (penicillin G sodium) interacted with Lys10, Asn31 and Thr85 residues *via* hydrogen bond (Fig. S24[†]). The carboxylic oxygen of the drug formed a salt bridge with Lys10, while the phenyl ring interacted with Phe3 by π - π stacking interactions. Compound **10** (tramadol hydrochloride)

interacted with the Arg23 *via* π -cation interaction (Fig. S25[†]). Compound **11** (nicotinic acid) interacted with Lys10 by hydrogen bonding, and by forming salt bridge and *via* aromatic interaction with the Leu44 (Fig. S26[†]).

Compound **12** (salbutamol sulphate) interacted with Glu34 and Thr85 residues of the protein by hydrogen bonds, and also by forming a salt bridge with Glu34 (Fig. S27[†]). Compound **13** (bupropion hydrochloride) interacted *via* forming a halogen bond with the Thr85 (Fig. S28[†]). Compound **14** (tenofovir disoproxil) was able to bind in the urease binding pocket *via* hydrophobic interactions (Fig. S29[†]). Compound **15** (rasagiline mesylate) interacted *via* π - π stacking, and by π -cationic interactions with Phe3, and Arg23, respectively (Fig. S30[†]). An aromatic hydrogen bond was also formed with Ala16.

Hence, the molecular docking studies further supported the interactions of these drugs with urease subunit gamma. All the drugs interacted mainly *via* non-covalent interactions, such as hydrogen bond, aromatic hydrogen bonding, π - π stacking, π -cation interactions, salt bridges and halogen bonding. These non-covalent interactions of drugs were formed with the binding site residues of the urease subunit gamma, mostly the Thr85, Lys10, Arg23 and Glu7. Further, MMGBSA analysis was performed to rank the ligands dock pose, and to predict their binding affinity. The binding energy of the ligands were estimated to be high in the range of -67.40 to -22.05 kcal mol⁻¹. Among various drugs, compounds **2**, **3**, **6**, **10**, and **12–14** showed higher binding energies for their interactions with urease subunit gamma.

MD simulation studies

Drugs **2**, **3**, **6**, **10**, and **12–14** that showed higher binding affinities in docking studies were subjected to MD simulation




Fig. 5 Docked pose of clidinium bromide (**3**) with urease subunit gamma. Protein–ligand interaction depicted in 3D representation (dotted lines), representing aromatic hydrogen bonding (light blue), π -cationic interaction (blue), and hydrogen bonding (black).




Fig. 6 Docked pose of ephedrine (**8**) with urease subunit gamma. Protein–ligand interaction depicted in 3D representation (dotted lines), representing hydrogen bonding (black), π -cationic interaction (blue), aromatic hydrogen bonding (light blue), and π - π stacking (red).

studies. The stability of UreA–drug complex in a dynamic environment was analyzed through 100 ns molecular dynamics (MD) simulation studies. The RMSD (root mean square deviation) plots of the protein ligand complexes indicated that drugs **2**, **3**, **9**, **10**, and **12–14** formed stable complexes with UreA. The

drug–UreA complexes of these drugs were stabilized with time evolution and no marked fluctuations were observed during the MD simulation time (Fig. 7, and S31[†]). Whereas, the UreA–drug complexes (**6** and **8**) did not stabilize with time evolution and marked fluctuations were observed, indicating that the ligand




Fig. 7 RMSD plots of (a) clidinium bromide (**3**), (b) tramadol HCl (**10**), (c) salbutamol sulphate (**12**), and (d) bupropion HCl (**13**) with UreA protein.




Fig. 8 Histogram of (a) clidinium bromide (3), (b) tramadol HCl (10), (c) salbutamol sulphate (12), and (d) bupropion HCl (13) interactions with UreA protein binding site residues.

has diffused out from its binding site (Fig. S32[†]). Furthermore, the protein–ligand contact maps of the complexes represented various intermolecular interactions (Fig. 8, and S33[†]). The histogram of the complexes indicated that the protein–ligand interacted mainly by water bridges, H-bond, and ionic interactions. The protein residues Lys10, Glu34, Asn34, and Thr85 were mostly involved for their interactions with binding ligands.

Thermal shift assay (TSA)

The temperature at which half of a protein unfolds is known as melting temperature (T_m). T_m is used to analyze a protein's thermal profile. When a ligand binds to protein, the free energy of protein–ligand binding may change the melting temperature of the protein. This change in the melting temperature, in the presence of ligand, corresponds to protein–ligand interactions.

All the drugs that exhibited interactions with UreA in STD-NMR spectra have shown effect on the melting temperature of UreA. T_m of UreA was determined to be 66.5 °C, without drug. Whereas, all the drugs molecule causes a decrease in UreA T_m between -0.6 to -3.4 °C (Fig. 9). These variations in T_m of UreA during the assay may indicate some conformational changes in its structure. Furthermore, the dissociation constant (K_d) for nicotinic acid was determined to be 70 mM when melting temperature was plotted against the nicotinic acid log concentration (Fig. S34[†]).

Urease inhibition assay

Since, the drugs showed interactions with urease subunit gamma, they were further analyzed for their urease inhibitory activity *in vitro*. The sequence similarity of urease subunit




Fig. 9 Graphical representation of variations in T_m values of UreA determined by DSF upon addition with the drug molecule. (Dark blue bars indicating the T_m value of UreA (20 μ M) without drugs, light blue bars indicate the variations in T_m value when drug molecule is added).

Table 3 % Inhibition of urease enzyme in the presence of drug molecules

Compound no.	Drug name	Mean % inhibition
1	Nicotinamide	-23.5 ± 6.65
2	Drotaverine HCl	17.6 ± 2.35
3	Clidinium bromide	-4.8 ± 1.02
4	Sulfanilamide	4.5 ± 3.58
5	Nicorandil	-12.2 ± 13.47
6	Hydroxychloroquine sulphate	63.7 ± 2.04
7	Glucosamine hydrochloride	54.2 ± 1.68
8	Ephedrine	72.0 ± 1.60
9	Penicillin G sodium	5.3 ± 3.32
10	Tramadol HCl	66.0 ± 0.39
11	Nicotinic acid	-42.2 ± 6.23
12	Salbutamol sulfate	59.4 ± 0.00
13	Bupropion HCl	9.1 ± 2.32
14	Tenofovir disoproxil	66.0 ± 2.04
15	Rasagiline mesylate	71.1 ± 0.45

gamma (MRSA252) with Jack bean (*Canavalia ensiformis*) urease is 49%, hence the commercially available Jack bean urease was used to assess the urease inhibitory activity. Table 3 presents the mean % inhibition of the urease enzyme with the drug molecules. Comparing to positive control (Jack bean urease), drugs **6**, **7**, **8**, **10**, **12**, **14**, and **15** showed inhibition of the urease enzyme. Among them drugs **8**, and **15** showed a significant inhibitory activity against Jack bean urease. Hence we propose on the basis of STD-NMR and *in vitro* inhibitory activity that compounds **8** and **15** can inhibit the urease activity, and most likely activity of urease gamma subunits.

In this study, we have specifically targeted the urease subunit gamma with US-FDA approved drugs, through STD-NMR spectroscopic techniques. While 15 drugs showed interactions with the selected target (UreA), there is always a possibility of off-target effect. This off-target effect may appear as interactions with other proteins of cellular pathways in human host. This may lead to potential adverse effects. However, we did not analyze the potential off-target effect of drugs in this study. Regardless of these limitations, our study has provided some insights into potential of these drugs as likely inhibitors of newly identified UreA subunit. This subunit was thus initially studied as potential target for the drug discovery and development studies against MRSA infections. However, to validate these results further mechanistic and inhibitory studies are required.

Conclusion

The current study was an effort to identify new drug targets. As a result, urease gamma subunit of MRSA was selected for antimicrobial agents, and targeted to identify potential inhibitors. The outcomes of the study includes cloning, expression, and purification of urease gamma subunit in *E. coli* expression system. The purified enzyme was used to screen various drugs as potential binders of the enzyme by using STD-NMR technique. Fifteen drugs were identified as hits against the urease

enzyme gamma subunit, and they also showed non-covalent interactions with the enzyme in molecular docking studies. These hits were further studied *via in vitro* inhibition assay, and by mechanistic techniques, against urease gamma, subunit of MRSA. Cumulatively results indicate that drugs **8** and **15** have the potential to inhibit urease subunit gamma and can serve as initial hits for further research as drug candidates against MRSA infections.

Data availability

The data supporting this article have been included as part of the ESI.†

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The authors acknowledge The Searle Company, Ltd Pakistan, for the financial support for several research projects in drug discovery field.

References

- 1 T. A. Taylor, and C. G. Unakal, in: *StatPearls*, StatPearls Publishing, Treasure Island, FL, USA, 2020.
- 2 A. S. Lee, H. de Lencastre, J. Garau, J. Kluytmans, S. Malhotra-Kumar, A. Peschel and S. Harbarth, *Nat. Rev. Dis. Prim.*, 2018, **4**, 1–23, DOI: [10.1038/nrdp.2018.33](https://doi.org/10.1038/nrdp.2018.33).
- 3 H. W. Boucher and G. R. Corey, *Clin. Infect. Dis.*, 2008, **46**, S344–S349, DOI: [10.1086/533590](https://doi.org/10.1086/533590).
- 4 T. A. Taylor, and C. G. Unakal, in *StatPearls*, StatPearls Publishing, Treasure Island, FL, USA, 2022.
- 5 S. Murchan, H. M. Aucken, G. L. O'Neill, M. Ganner and B. D. Cookson, *J. Clin. Microbiol.*, 2004, **42**, 5154–5160, DOI: [10.1128/jcm.42.11.5154-5160.2004](https://doi.org/10.1128/jcm.42.11.5154-5160.2004).
- 6 C. Zhou, F. Bhinderwala, M. K. Lehman, V. C. Thomas, S. S. Chaudhari, K. J. Yamada, K. W. Foster, R. Powers, T. Kielian and P. D. Fey, *PLoS Pathog.*, 2019, **15**(1), e107538, DOI: [10.1371/journal.ppat.1007538](https://doi.org/10.1371/journal.ppat.1007538).
- 7 S. Jing, X. Kong, L. Wang, H. Wang, J. Feng, L. Wei, Y. Meng, C. Liu, X. Chang, Y. Qu, J. Guan, H. Yang, C. Zhang, Y. Zhao and W. Song, *Microbiol. Spectr.*, 2022, **10**, 02340, DOI: [10.1128/spectrum.02340-21](https://doi.org/10.1128/spectrum.02340-21).
- 8 H. L. Mobley and R. P. Hausinger, *Microbiol. Rev.*, 1989, **53**, 85–108, DOI: [10.1128/mr.53.1.85-108.1989](https://doi.org/10.1128/mr.53.1.85-108.1989).
- 9 O. D. Merloni, B. Zambelli, F. Agostini, M. Bazzani, F. Musiani and S. Ciurli, *Biochim. Biophys. Acta, Proteins Proteomics*, 2014, **1844**, 1662–1674, DOI: [10.1016/j.bbapap.2014.06.016](https://doi.org/10.1016/j.bbapap.2014.06.016).
- 10 Y. S. Nim and K. B. Wong, *Inorganics*, 2019, **7**, 85, DOI: [10.3390/inorganics7070085](https://doi.org/10.3390/inorganics7070085).
- 11 H. L. Mobley, M. D. Island and R. P. Hausinger, *Microbiol. Rev.*, 1995, **59**, 451–480, DOI: [10.1128/mr.59.3.451-480.1995](https://doi.org/10.1128/mr.59.3.451-480.1995).

- 12 K. Oki, K. Washio, D. Matsui, S. Kato, Y. Hirata and M. Morikawa, *Biosci. Biotechnol. Biochem.*, 2010, **74**, 583–589, DOI: [10.1271/bbb.90796](https://doi.org/10.1271/bbb.90796).
- 13 M. Vitolo, *World J. Pharm. Pharm. Sci.*, 2022, **11**, 96–135, DOI: [10.20959/wjpps20223-21380](https://doi.org/10.20959/wjpps20223-21380).
- 14 S. Murchan, H. M. Aucken, G. L. O'Neill, M. Ganner and B. D. Cookson, *J. Clin. Microbiol.*, 2004, **42**, 5154–5160, DOI: [10.1128/jcm.42.11.5154-5160.2004](https://doi.org/10.1128/jcm.42.11.5154-5160.2004).
- 15 P. Z. Konieczna, M. Kwinkowski, B. Kolesinska, J. Fraczyk, Z. Kaminski and W. Kaca, *Curr. Protein Pept. Sci.*, 2012, **13**, 789–806, DOI: [10.2174/138920312804871094](https://doi.org/10.2174/138920312804871094).
- 16 M. Mayer and B. Meyer, *Angew. Chem., Int. Ed.*, 1999, **38**, 1784–1788, DOI: [10.1002/\(SICI\)1521-3773\(19990614\)38:12<1784::AID-ANIE1784>3.0.CO;2-Q](https://doi.org/10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q).
- 17 O. Cala and I. Krimm, *J. Med. Chem.*, 2015, **58**, 8739–8742, DOI: [10.1021/acs.jmedchem.5b01114](https://doi.org/10.1021/acs.jmedchem.5b01114).
- 18 L. Hall, A. Sohail, E. J. Cabrita, C. MacDonald, T. Stockner, H. H. Sitte, J. Angulo and F. MacMillan, *Sci. Rep.*, 2020, **10**, 16483, DOI: [10.1038/s41598-020-73443-z](https://doi.org/10.1038/s41598-020-73443-z).
- 19 U. Salar, A. Wahab and M. I. Choudhary, *Biochimie*, 2022, **201**, 148–156, DOI: [10.1016/j.biochi.2022.06.004](https://doi.org/10.1016/j.biochi.2022.06.004).
- 20 M. B. Waterhouse, S. Bienert, G. Studer, G. Tauriello, R. Gumienny, F. T. Heer, T. A. P. de Beer, C. Rempfer, L. Bordoli, R. Lepore and T. Schwede, *Nucleic Acids Res.*, 2018, **46**, 296–303, DOI: [10.1093/nar/gky427](https://doi.org/10.1093/nar/gky427).
- 21 H. B. Banks, Y. Cao, A. Cho, W. Damm, R. Farid, A. Felts, T. Halgren, D. Mainz, J. Maple, R. Murphy, D. Philipp, M. Repasky, L. Zhang, B. Berne, R. Friesner, E. Gallicchio and R. Levy, *J. Comput. Chem.*, 2005, **26**, 1752–1780, DOI: [10.1002/jcc.20292](https://doi.org/10.1002/jcc.20292).
- 22 Z. Vajo, J. Fawcett and W. C. Duckworth, *Endocr. Rev.*, 2001, **22**, 706–717, DOI: [10.1210/edrv.22.5.0442](https://doi.org/10.1210/edrv.22.5.0442).
- 23 B. Meyer, *J. Am. Chem. Soc.*, 2001, **123**, 6108–6017, DOI: [10.1021/ja0100120](https://doi.org/10.1021/ja0100120).
- 24 H. M. Rolfe and J. Cosmet, *Dermatol.*, 2014, **13**, 324–328, DOI: [10.1111/jocd.12119](https://doi.org/10.1111/jocd.12119).
- 25 R. R. Rai and S. Nijhawan, *Saudi J. Gastroenterol.*, 2021, **27**, 136–143, DOI: [10.4103/sjg.SJG_266_20](https://doi.org/10.4103/sjg.SJG_266_20).
- 26 S. M. El-Megharbel, M. S. Refat, G. Pu, X. Yu, G. Pu and F. Xi, *Spectrosc. Spectr. Anal.*, 2021, **41**, 3316–3320, DOI: [10.3964/j.issn.1000-0593\(2021\)10-3316-05](https://doi.org/10.3964/j.issn.1000-0593(2021)10-3316-05).
- 27 C. R. Vanoni, J. P. Winiarski, G. R. Nagurniak, H. A. Magosso and C. L. Jost, *Electroanalysis*, 2019, **31**, 867–875, DOI: [10.1002/elan.201800832](https://doi.org/10.1002/elan.201800832).
- 28 H. Ashour, M. H. Elsayed, S. Elmorsy and I. A. Harb, *Clin. Exper. Pharmacol. Physiol.*, 2020, **47**, 1791–1797, DOI: [10.1111/1440-1681.13395](https://doi.org/10.1111/1440-1681.13395).
- 29 M. Perrone, V. Laquintana, A. A. Lopodota, A. Cutrignelli, A. Lopalco, M. Franco, A. Pepe, S. Fontana and N. Denora, *Data Brief*, 2020, **33**, 106575, DOI: [10.1016/j.dib.2020.106575](https://doi.org/10.1016/j.dib.2020.106575).
- 30 D. M. Carrasco, J. I. Ayala and J. P. Casals, *Actas Dermosifiliogr*, 2022, **113**, T166–T175, DOI: [10.1016/j.ad.2022.01.012](https://doi.org/10.1016/j.ad.2022.01.012).
- 31 H. W. Chiu, L. H. Li, C. Y. Hsieh, Y. K. Rao, F. H. Chen, A. Chen, S. M. Ka and K. F. Hua, *Sci. Rep.*, 2019, **9**, 1–3, DOI: [10.1038/s41598-019-42130-z](https://doi.org/10.1038/s41598-019-42130-z).
- 32 S. Wu, J. Hu, L. Wei, Y. Du, X. Shi and L. Zhang, *Food Chem.*, 2014, **148**, 196–203, DOI: [10.1016/j.foodchem.2013.10.044](https://doi.org/10.1016/j.foodchem.2013.10.044).
- 33 C. G. Chen, S. Hou, J. Lv, Y. Zhang, H. Zhang and J. Xu, *Appl. Catal. B Environ.*, 2020, **266**, 118614, DOI: [10.1016/j.apcatb.2020.118614](https://doi.org/10.1016/j.apcatb.2020.118614).
- 34 S. Tuglar, E. A. Alasehir and O. Selvi, *Rev. Bras. Anesthesiol.*, 2018, **68**, 69–74, DOI: [10.1016/j.bjane.2017.06.004](https://doi.org/10.1016/j.bjane.2017.06.004).
- 35 J. Zhang, Z. Xiong, J. Wei, Y. Song, Y. Ren, D. Xu and B. Lai, *Chem. Eng. J.*, 2020, **383**, 123144, DOI: [10.1016/j.cej.2019.123144](https://doi.org/10.1016/j.cej.2019.123144).
- 36 M. Vazzana, T. Andreani, J. Fangueiro, C. Faggio, C. Silva, A. Santini, M. L. Garcia, A. M. Silva and E. B. Souto, *Biomed. Pharmacother.*, 2015, **70**, 234–238, DOI: [10.1016/j.biopha.2015.01.022](https://doi.org/10.1016/j.biopha.2015.01.022).
- 37 Z. Tamanai-Shacoori, V. Shacoori, A. Jolivet-Gougeon, J. M. V. Van, M. Repère, P. Y. Donnio and M. Bonnaure-Mallet, *Anesth. Analg.*, 2007, **105**, 524–527, DOI: [10.1213/01.ane.0000267525.51017.b8](https://doi.org/10.1213/01.ane.0000267525.51017.b8).
- 38 E. T. B. Gille, K. Ahmed and S. Offermanns, *Annu. Rev. Pharmacol. Toxicol.*, 2008, **48**, 79–106, DOI: [10.1146/annurev.pharmtox.48.113006.094746](https://doi.org/10.1146/annurev.pharmtox.48.113006.094746).
- 39 K. Paruch, A. Biernasiuk, D. Khylyuk, R. Paduch, M. Wujec and Ł. Popiołek, *Int. J. Mol. Sci.*, 2022, **23**, 2823, DOI: [10.3390/ijms23052823](https://doi.org/10.3390/ijms23052823).
- 40 M. S. Ferdynand and A. Nokhodchi, *Drug Deliv. Transl. Res.*, 2020, **10**, 1418–1427, DOI: [10.1007/s13346-020-00707-6](https://doi.org/10.1007/s13346-020-00707-6).
- 41 M. Vandeveld, P. M. Tulkens, G. G. Muccioli and F. V. Bambeke, *J. Antimicrob. Chemother.*, 2015, **70**, 1713–1726, DOI: [10.1093/jac/dkv032](https://doi.org/10.1093/jac/dkv032).
- 42 M. Manjushree and H. D. Revanasiddappa, *Spectrochim. Acta, Part A*, 2019, **209**, 264–273, DOI: [10.1016/j.saa.2018.10.047](https://doi.org/10.1016/j.saa.2018.10.047).
- 43 M. L. Cottrell, K. H. Yang, H. M. A. Prince, C. Sykes, N. White, S. Malone, E. S. Dellon, R. D. Madanick, N. J. Shaheen, M. G. Hudgens, J. Wulff, K. B. Patterson, J. A. E. Nelson and A. D. M. Kashuba, *J. Infect. Dis.*, 2016, **214**, 55–64, DOI: [10.1093/infdis/jiw077](https://doi.org/10.1093/infdis/jiw077).
- 44 P. Patel, A. Pol, D. Kalaria, A. A. Date, Y. Kalia and V. Patravale, *Eur. J. Pharm. Biopharm.*, 2021, **165**, 66–74, DOI: [10.1016/j.ejpb.2021.04.026](https://doi.org/10.1016/j.ejpb.2021.04.026).